Welcome to our dedicated page for Senseonics Holdings news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics Holdings stock.
Senseonics Holdings, Inc. (symbol: SENS) is a pioneering medical technology firm based in Germantown, Maryland. The company's primary focus is on developing and commercializing advanced glucose monitoring systems that significantly improve the lives of people managing diabetes. Utilizing cutting-edge fluorescence sensing technology, Senseonics has designed the Eversense Continuous Glucose Monitoring (CGM) System, recognized for being the first fully implantable CGM system. This system comprises a tiny sensor implanted under the skin, an external smart transmitter, and a user-friendly mobile application, allowing for real-time glucose monitoring without the need for a dedicated receiver.
The Eversense CGM System stands out for its accuracy and stability throughout its extended sensor life, offering continuous glucose monitoring for up to 180 days. This long-term solution provides an alternative to traditional short-term CGMs, catering to individuals who require a more stable and reliable glucose monitoring option.
Senseonics has established strong partnerships, including a notable collaboration with Ascensia Diabetes Care, which ensures that their innovative solutions reach a global audience. Their latest product, the Eversense E3 CGM System, is part of an extended assistance program known as the Eversense Payment Assistance and Simple Savings (PASS) Program. This program offers eligible individuals in the U.S. the opportunity to access the Eversense E3 systems at a significantly reduced out-of-pocket cost of $99 for each six-month period, thereby making continuous glucose monitoring more affordable.
Senseonics is committed to advancing diabetes management technology, as evidenced by their continued innovation and dedication to improving accessibility to their products. The company's forward-looking approach and strategic alliances position them as a key player in the medical technology landscape, specifically in the context of diabetes management.
Senseonics Holdings, Inc. (NYSE American: SENS) has announced equity grants to 17 new employees under its 2019 Inducement Plan. On April 1, 2022, the Compensation Committee granted non-qualified stock options for an aggregate of 142,000 shares at an exercise price of $1.94, reflecting the closing stock price on that date. The options will vest over four years, contingent on the employees' continued service. Senseonics aims to expand its Eversense CGM System to more diabetes patients in the U.S. and globally, enhancing their product offerings.
Senseonics Holdings, Inc. (SENS) reported its financial results for Q4 and the full year 2021. The fourth quarter total revenue reached $4.0 million, a slight increase from $3.9 million in Q4 2020. The significant net income of $84.4 million contrasts sharply with a net loss of $101.6 million in Q4 2020. Full-year revenue surged to $13.7 million, up from $4.9 million in 2020, driven by post-Covid sales and the transition of Eversense commercialization to Ascensia. Looking forward, the 2022 global revenue outlook is estimated between $14.0 million and $18.0 million.
Senseonics Holdings, Inc. (AMEX: SENS) will release its fourth quarter and full year 2021 financial results on March 1, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss performance details. Investors can access the call by dialing specific numbers or through a webcast on the company’s website. Senseonics focuses on developing long-term, implantable continuous glucose monitoring (CGM) systems, with products like Eversense® and Eversense® E3 designed to enhance diabetes management.
Ascensia Diabetes Care announced FDA approval for the next-generation Eversense® E3 Continuous Glucose Monitoring (CGM) System, developed by Senseonics (NYSE American: SENS). This system boasts a sensor life of up to six months, significantly enhancing patient convenience with only two sensor insertions required annually. The E3 sensor demonstrates exceptional accuracy, with a mean absolute relative difference (MARD) of 8.5% from the PROMISE Study. The product aims to launch in the U.S. in Q2 2022, supported by programs to improve patient access and affordability.
Senseonics Holdings, Inc. has announced FDA approval for the Eversense® E3 Continuous Glucose Monitoring (CGM) System, the only long-term implantable CGM, which provides accurate glucose monitoring for up to 6 months. This next-generation device features proprietary SBA technology and is set to be available publicly through Ascensia Diabetes Care in Q2 2022. The company projects 2022 global net revenue between $14 million and $18 million, with ongoing investment in R&D for further product development.
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants under its 2019 Inducement Plan to attract new employees. On
Senseonics Holdings, Inc. (NYSE American: SENS) announced updates regarding their next-generation Eversense 180-day continuous glucose monitoring (CGM) system. The FDA's review for the PMA supplement is nearing completion, with a decision expected soon. The company is working with Ascensia Diabetes Care to ensure a smooth transition to the new system, including marketing campaigns and reimbursement plans. Senseonics maintains its revenue outlook for 2021, projecting net revenues between $12 million and $15 million.
Senseonics Holdings, Inc. (SENS) announced the receipt of the CE mark for its Eversense NOW Remote Monitoring App for Android, enhancing its long-term continuous glucose monitoring system. The app, which offers real-time glucose data monitoring for users and their families, is expected to launch in Q1 2022. The Eversense XL CGM System allows glucose measurement for up to 180 days. The company emphasizes its commitment to transforming diabetes management with innovative technology.
Senseonics Holdings, Inc. (SENS) reported third quarter 2021 revenue of $3.5 million, a significant increase from $0.8 million in Q3 2020. U.S. revenue was $0.6 million, while international sales reached $2.9 million. The net income surged to $42.9 million or $0.10 per share, a turnaround from a net loss of $23.4 million a year prior. However, the company anticipates 2021 global net revenue to fall within $12 million to $15 million due to uncertainties related to COVID-19 and FDA reviews.
Senseonics Holdings, Inc. (AMEX: SENS) has announced participation in two upcoming investor conferences. Management will engage in a virtual fireside chat on November 16, 2021, at 8:40am ET during the Stifel 2021 Virtual Healthcare Conference. Additionally, a presentation will be available on November 18, 2021, at 3:00am ET at the Jefferies London Healthcare Conference. Interested parties can access live and on-demand webcasts on the Company’s website. Senseonics focuses on long-term glucose monitoring systems for diabetes management.
FAQ
What is the current stock price of Senseonics Holdings (SENS)?
What is the market cap of Senseonics Holdings (SENS)?
What does Senseonics Holdings, Inc. specialize in?
What is the Eversense Continuous Glucose Monitoring (CGM) System?
How long can the Eversense CGM System monitor glucose levels?
What is the Eversense Payment Assistance and Simple Savings (PASS) Program?
How does Senseonics' CGM technology benefit people with diabetes?
Where is Senseonics Holdings, Inc. headquartered?
Who are Senseonics' key partners?
How can I learn more about the Eversense CGM System?
Is the Eversense CGM System available outside the United States?
What is the mission of Senseonics Holdings, Inc.?
